Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.

Anti-inflammatory Antibacterial Anticancer Antiparasitic Antiviral Biological activities Imidazo[1,2-b]pyridazine Metabolic disorders Radiotracers Sleeping disorders Structure-activity relationship Thymic enhancers

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Dec 2021
Historique:
received: 28 06 2021
revised: 09 09 2021
accepted: 20 09 2021
pubmed: 5 10 2021
medline: 27 1 2022
entrez: 4 10 2021
Statut: ppublish

Résumé

Imidazo[1,2-b]pyridazine scaffold represents an important class of heterocyclic nucleus which provides various bioactives molecules. Among them, the successful kinase inhibitor ponatinib led to a resurgence of interest in exploring new imidazo[1,2-b]pyridazine-containing derivatives for their putative therapeutic applications in medicine. This present review intends to provide a state-of-the-art of this framework in medicinal chemistry from 1966 to nowadays, unveiling different aspects of its structure-activity relationships (SAR). This extensive literature surveil may guide medicinal chemists for the quest of novel imidazo[1,2-b]pyridazine compounds with enhanced pharmacokinetics profile and efficiency.

Identifiants

pubmed: 34607244
pii: S0223-5234(21)00716-9
doi: 10.1016/j.ejmech.2021.113867
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Anti-Inflammatory Agents 0
Antineoplastic Agents 0
Pyridazines 0
imidazo(1,2-b)pyridazine 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

113867

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Amanda Garrido (A)

Université de Tours, EA 7502 SIMBA Synthèse et Isolement de Molécules Bioactives, 31 Avenue Monge, Tours, France. Electronic address: amanda.garrido@univ-lyon1.fr.

Gonzalo Vera (G)

Normandie Univ, UNICAEN, Centre D'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Pierre-Olivier Delaye (PO)

Université de Tours, EA 7502 SIMBA Synthèse et Isolement de Molécules Bioactives, 31 Avenue Monge, Tours, France.

Cécile Enguehard-Gueiffier (C)

Université de Tours, EA 7502 SIMBA Synthèse et Isolement de Molécules Bioactives, 31 Avenue Monge, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH